Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Astellas to File Japan NDA for Izervay This Month
February 5, 2025
- Ono Axes ONO-2910 Peripheral Neuropathy Program and More
February 4, 2025
- Mochida President Hails Govt Initiatives to Drive Biosimilar Uptake
February 4, 2025
- Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
- ASKA to Boost Stake in Vietnam’s Ha Tay for Generic Biz Base
February 4, 2025
- Dato-DXd Gets EU Panel Backing for Breast Cancer: Daiichi Sankyo
February 4, 2025
- Daiichi Sankyo, Takeda Restricting Shipments of Mumps Vaccines
February 3, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Shionogi to Bolster New Drug Development in China
February 3, 2025
- Daiichi Sankyo Assigns COO Okuzawa as CEO from April
February 3, 2025
- Datroway Now in PIII Study for Adjuvant NSCLC Setting: Daiichi Sankyo
February 3, 2025
- Daiichi Sankyo to Promote COO Okuzawa to CEO
January 31, 2025
- Sarepta Drops DMD Drug Patent Claim against Nippon Shinyaku in Japan
January 31, 2025
- Novo Launches Once-Weekly Insulin Awiqli in Japan
January 31, 2025
- J&J Files Nipocalimab for Generalized Myasthenia Gravis in Japan
January 31, 2025
- Chugai Logs Record Earnings in 2024 on Upbeat Exports to Roche
January 31, 2025
- Chugai, SoftBank in AI Deal to Speed Up Drug Development
January 31, 2025
- Chugai, GSK Join Hands in Anti-Dengue Antibody Development
January 31, 2025
- Takeda Drops Epilepsy Med Soticlestat after PIII Miss
January 31, 2025
- Takeda Ups Full-Year Guidance on Slower Vyvanse Generic Erosion
January 31, 2025
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…